Compare Ascendis Pharma A/S (ASND) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Suncor Energy Inc. — how do they compare? Ascendis Pharma A/S trades at $263.68 (market cap $17.74B), while Suncor Energy Inc. trades at $61.02 (market cap $69.71B). The key difference: Suncor Energy Inc. is far larger — about 3.9× Ascendis Pharma A/S's market cap, and Suncor Energy Inc. pays a 2.85% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SU | |
|---|---|---|
Market Cap | $17.74B | $69.71B |
Sector | Health | Energy |
52-Week High | $277.18 | $69.73 |
52-Week Low | $163.32 | $38.17 |
Enterprise Value | $18.11B | $77.84B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Suncor Energy (SU) trades at $59.25, up 1.3% today, with strong analyst support (74% buy ratings) and bullish technical signals. The stock shows solid fundamentals with a P/E of 15.99, net margin of 11.62%, and consistent dividend payments. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 results exceeded forecasts. Cash flow remains positive with $166M net inflow in 2025.
Outlook remains positive with expected revenue growth to $54.5B in 2026 and improving profit margins. Key risks include oil price volatility and operational challenges. The stock presents value opportunity with attractive valuation metrics and strong institutional support, though investors should monitor Q2 2026 earnings results against the $2.26 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
